CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 21 enrolled
Drug / intervention
Bevacizumab +1 moredrug
Likely dose
Bevacizumab 15 mg/kg IV every 21 days plus Erlotinib 150 mg orally dailyAI-extracted
Key inclusion· 7
  • ✓Histologically or cytologically confirmed hepatocellular carcinoma diagnosis
  • ✓Unresectable disease or not suitable surgical candidates
  • ✓ECOG performance status 0-2
  • ✓Measurable or evaluable disease
Key exclusion· 10
  • ✕Surgically resectable disease
  • ✕Brain metastases
  • ✕Active bacterial infections
  • ✕Uncontrolled hypertension >150/100 mmHg

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00287222
NCT00287222Phase 2Completed
CompareCT.gov

Bevacizumab and Erlotinib in Inoperable and Metastatic Hepatocellular Carcinoma

University of Arkansas·interventional·Posted Feb 6, 2006·Updated Jul 15, 2011

In Brief

A Phase 2 clinical trial evaluating Bevacizumab and Erlotinib for Hepatocellular Carcinoma. Completed, enrolled 21 participants across 2 sites.

Detailed Summary

The primary efficacy endpoint will be the proportion of subjects that remain free of progression at the 27th week following the onset of treatment. Secondary objectives include the subject's time in weeks from treatment onset to documented disease progression as assessed by the RECIST criteria, response rate, median and overall survival, safety and tolerability.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatocellular Carcinoma
CountriesUnited States
CollaboratorsGenentech, Inc.

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 6, 2006
Enrollment StartFeb 1, 2006
Primary CompletionSep 1, 2010
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 20.4 years ago

Interventions

Bevacizumabdrug

15 mg/KG I.V. every 21 days

Erlotinibdrug

150 mg orally every day